當(dāng)前位置：   首頁 > 需求大廳

1、Clinical Features and Molecular Genetics of HSD387 Deficiency and AKRlD1 Deficiency A case report of inborn errors of bile acid synthesis 2、3B-hydroxy-△5-C27 steroid dehydrogenase deficiency: a case report 3、Hallas G. Chem. and Ind. 1972,691 4、Chemical and biological characterization of iron-protein succinylate (ITF 282)' 5、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

EP10.0藥典： 1、Piperacillin Sodium EP10.0 2、替加環(huán)素Tigecycline EP10.0 3、阿托品atropine EP10.0 4、硫酸阿托品 EP10.0 5、2.6.31 EP10.0 6、EP10.0: Salmeterol Xinafoate 7、EP10.0: Preparations for inhalation 8、EP10.0: Pressurised pharmaceutical preparations" 9、EP10:ceftazidime 10、Formoterol Fumarate EP10.0 11、乳酸依沙吖啶Ethacridine lactate monohydrate EP10.0 12、Aspartame的EP10.0標(biāo)準(zhǔn) 13、EP10.0 3.1.9 14、perindopril tert-butylamine的EP10.1標(biāo)準(zhǔn) 15、CALCIUM LEVOFOLINATE HYDRATE EP10.0 16、Deslanoside EP10 17、Inhalation powders EP10 18、Fluconazole EP10 19、Nifedipine EP10 20、Calcium Dobesilate Monohydrate 羥苯磺酸鈣原料藥EP10.0的標(biāo)準(zhǔn) 21、EP10.0 Ipratropium bromide 22、Voriconazole EP10.0 23、Magnesium Stearate硬脂酸鎂 EP10.0 24、Colloidal Anhydrous Silica膠態(tài)無水二氧化硅 EP10.0 25、Purified water 純化水 EP10.0 26、Povidone (K-90) 聚維酮 (K-90) EP10.0 27、Hydroxypropyl cellulose (EF)羥丙纖維素 (EF) EP10.0 28、HPMC E-15羥丙甲纖維素E-15 EP10.0 29、Purified Talc 滑石粉 EP10.0 30、Pregelatinised Starch 預(yù)膠化淀粉 EP10.0 31、Lactose Monohydrate一水乳糖 EP10.0 32、lsopropyl Alcohol異丙醇 EP10.0 33、Titanium dioxide二氧化鈦 EP10.0 34、Polyethylene glycol 400 聚乙二醇400 EP10.0 35、氨丁三醇 TROMETAMOL EP10.0 36、依地酸鈣鈉 SODIUM CALCIUM EDETATE EP10.0 37、碘帕醇 IOPAMIDOL EP10.0 38、甘露醇 MANNITOL 查EP10.0 39、Macrogol 4000 EP10.0 40、鹽酸二甲雙胍Metformin hydrochloride，EP10.0 41、Polyoxyl castor oil EP10.0 42、Ascorbic Acid-EP10.0 43、EP10.0中的（5.1.8） 44、EP10.0中的（5.1.4） 45、Carboxymethylcellulose sodium的最新歐洲藥典，然后這個monograph（專著）里面有一個取代度的具體方法。 EP10.0 46、Tranexamic Acid EP10.0 47、歐洲藥典10.0版Starches hydrocyethyl 48、Dextrose和Glucose monohydrate EP10標(biāo)準(zhǔn) 49、Oxcarbazepine EP10標(biāo)準(zhǔn) 50、Human albumin solution EP10標(biāo)準(zhǔn) 51、Cefoperazone Sodium EP10.0 52、Sulbactam Sodium EP10.0 53、Azithromycin、 EP10標(biāo)準(zhǔn) 54、Aripiprazole EP10.0 55、 Candesartan cilexetil EP10.0 56、Clopidogrel besilate EP10.0 57、Clopidogrel hydrogen sulfate EP10.0 58、Clopidogrel hydrochloride EP10.0 59、Duloxetine hydrochloride EP10.0 60、Galantamine hydrobromide EP10.0 61、Irbesartan EP10.0   [更多]

100868-201603 【CAS 號】87 -62 -7 中檢院 2，6-二甲基苯胺   [更多]

本公司需要一份比較完善且新的針對臨床試驗全過程的質(zhì)量管理體系文件，最好是來源于知名大公司的質(zhì)控文件   [更多]

急需液體敷料一類醫(yī)療器械備案全套申請資料及生產(chǎn)備案資料 產(chǎn)品風(fēng)險分析報告 產(chǎn)品技術(shù)要求 產(chǎn)品檢驗報告 臨床評價資料 產(chǎn)品說明書及標(biāo)簽樣稿 與產(chǎn)品研制、生產(chǎn)有關(guān)的質(zhì)量管理體系文件 生產(chǎn)制造信息 符合性聲明   [更多]

1、targeting inhaled steroids 文獻 2、Minerva Dietol Gastroenterol. 1989 Jul-Sep;35(3):175-89. [A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. [Article in Italian] Del Tacca M, Danesi R, Blandizzi C, Bernardini MC. 3、See 1 citation found by title matching your search: J Pharmacol. 1985;16 Suppl 2:145-69. [MI cholinergic receptors of gastric secretion: current status]. [Article in French]、 4、Carrigan PJ, Papp K, Schulz G, Venable T. Bioavailability of valproate from divalproex sodium tablets. Abbott Laboratories, North Chicago, IL (unpublished data). 5、MITOXANTRONE - MECHANISM OF ACTION, ANTITUMOR-ACTIVITY, PHARMACOKINETICS, EFFICACY IN THE TREATMENT OF SOLID TUMORS AND LYMPHOMAS, AND TOXICITY，文獻 6、American Journal of Kidney Diseases Volume 70, Issue 6, December 2017, Pages 737-751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)   [更多]

需要間苯三酚EP最新版質(zhì)量標(biāo)準(zhǔn)，求助   [更多]

1、Nimesulide - a non-steroidal anti-inflammatory drug, a preferential cyclooxygenase-2 inhibitor 【出處】Vutreshni bolesti. 2000;32(1):33-6. 2、Bioequivalence study between two slow release batches ofindapamide SR 1.5 mg with different dissolution pro- files after repeated oral administration over 7 days in 12 healthy volunteers: a randomised double blind cross over study. Fulmer Hall, UK: Servier, 1993. Report No.: NP 910 3、Schiavi P, Jochemsen R, Hiley M, et al. Pharmacokinetics ofslow and immediate release formulations of indapamide after single oral administration under fasting conditions and after food, in healthy volunteers. Eur J Drug Metab Pharmacokinet 1996; Spe- cial Issue: 42 4、找一篇97年的政策法規(guī)文件，標(biāo)題：國家醫(yī)藥管理局國藥字（97）253號文件 5、Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder. Jpn J Clin Psychopharmacol 2009;12:1613-1634   [更多]

本公司臨床部門需要一份比較完善且新的針對臨床試驗全過程的質(zhì)量管理體系文件。質(zhì)量夠好可追加獎勵。   [更多]

制定臨床質(zhì)量管理計劃，并說明理由。   [更多]